AtriCure (NASDAQ:ATRC) Upgraded to “Strong-Buy” at Zacks Research

AtriCure (NASDAQ:ATRC) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks reports.

A number of other research firms also recently issued reports on ATRC. Weiss Ratings raised AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Stifel Nicolaus set a $65.00 price target on AtriCure in a research note on Thursday, September 17th. Piper Sandler restated an “overweight” rating and issued a $70.00 price objective (up from $60.00) on shares of AtriCure in a report on Wednesday. Citizens Jmp upped their price objective on shares of AtriCure from $52.00 to $68.00 and gave the stock a “market outperform” rating in a research note on Wednesday, October 21st. Finally, Canaccord Genuity Group increased their target price on shares of AtriCure from $55.00 to $67.00 and gave the stock a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.80.

AtriCure Stock Down 6.5%

Shares of NASDAQ:ATRC opened at $61.28 on Wednesday. AtriCure has a 52-week low of $25.36 and a 52-week high of $66.02. The stock has a market cap of $3.12 billion, a P/E ratio of 159.83 and a beta of 1.23. The business’s 50 day moving average is $56.62 and its 200 day moving average is $38.63. The company has a quick ratio of 3.19, a current ratio of 4.33 and a debt-to-equity ratio of 0.11.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.23. The company had revenue of $154.45 million for the quarter, compared to the consensus estimate of $151.05 million. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. Sell-side analysts predict that AtriCure will post 0.29 EPS for the current year.

Insider Activity at AtriCure

In related news, Director Regina Groves sold 5,313 shares of AtriCure stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $54.22, for a total transaction of $288,070.86. Following the transaction, the director directly owned 34,546 shares of the company’s stock, valued at $1,873,084.12. This trade represents a 13.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Salvatore Privitera sold 8,404 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $65.00, for a total transaction of $546,260.00. Following the completion of the transaction, the insider directly owned 134,341 shares of the company’s stock, valued at $8,732,165. This trade represents a 5.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 39,026 shares of company stock valued at $2,172,263 over the last ninety days. 4.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ATRC. BlackRock Inc. bought a new position in shares of AtriCure in the 2nd quarter worth $125,198,000. Bank of America Corp DE purchased a new stake in shares of AtriCure during the 2nd quarter worth $24,465,000. Grandeur Peak Global Advisors LLC purchased a new stake in shares of AtriCure during the 2nd quarter worth $16,435,000. Osterweis Capital Management Inc. bought a new stake in AtriCure during the second quarter valued at about $14,028,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in AtriCure during the second quarter valued at about $9,388,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.17 per share, ahead of the $0.06-per-share loss analysts expected, while revenue of $154.45 million also topped estimates. AtriCure raised its 2026 revenue guidance to $606 million–$610 million and projected adjusted EBITDA of $91 million–$94 million. AtriCure reports third-quarter results AtriCure outlook and study enrollment
• Positive Sentiment: Several analysts raised price targets following the results. Piper Sandler reiterated Overweight and raised its target to $70; Needham also set a $70 target, while Canaccord raised its target to $67 with a Buy rating. These revisions signal continued confidence in AtriCure’s growth prospects. Analysts raise forecasts Piper Sandler rating
• Neutral Sentiment: JPMorgan raised its target substantially, to $62, but maintained a Neutral rating—suggesting limited upside in its view. JPMorgan rating and target
• Negative Sentiment: A valuation-focused article questioned whether strong results and the higher outlook are already reflected in the stock, which could constrain further gains after its recent run-up. AtriCure valuation discussion
• Negative Sentiment: Insider Salvatore Privitera sold 8,404 shares for about $546,000. The sale was made under a pre-arranged Rule 10b5-1 plan, and he retained 134,341 shares, making the signal less concerning than an unplanned sale. SEC insider filing

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.